COVID-19 Monoclonal Antibody Treatment Training

Issued by CME Outfitters

Earners have developed the skills needed to integrate screening assessments for the early and accurate diagnosis of mild-to-moderate COVID-19 to guide treatment decision-making in high-risk patient groups. They are competent in skills such as applying the latest data on the efficacy and safety of monoclonal antibody therapies to treatment decisions and implementing strategies to address knowledge and practice barriers to patient access to infusion service for monoclonal antibody therapy.

Type Learning
Level Foundational
Time Hours
Cost Free

Additional Details

Skills

COVID Monoclonal Antibody Treatment
Health Assessment
Patient Access To Treatment
Risk Factors For COVID Disease Severity

Earning Criteria

Earners must complete the activity, "Bench to Bedside: The Growing (Anti)body of Evidence for the Treatment of Mild-to-Moderate COVID-19."
Post-test, credit request form, and activity evaluation must be completed. 75% pass rate required.

Evidence

Bench to Bedside: The Growing (Anti)body of Evidence for the Treatment of Mild-to-Moderate COVID-19

Participants of this CME Outfitters course learned the latest data on the efficacy and safety of mAb therapies and strategies for addressing knowledge and practice barriers to improve patient access to these therapies.